US2016024041A1PendingUtilityA1

PPARs AGONIST ACTIVITY ENHANCING DRUG

Assignee: IINUMA MUNEKAZUPriority: Mar 27, 2012Filed: Jul 30, 2015Published: Jan 28, 2016
Est. expiryMar 27, 2032(~5.7 yrs left)· nominal 20-yr term from priority
Inventors:Munekazu Iinuma
A61P 3/10A61P 43/00A61P 9/12A61P 3/06A61P 3/04A61K 9/0053A61K 31/366A61P 3/00C07D 309/32
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A lifestyle disease improving drug that enhances PPARα, δ and γ agonist activities that includes a compound having the lactone structure in accordance with the chemical formula 6-alkyl-5,6-dihydro-2H-pyran-2-one, the alkyl containing 4, 5, or 6 carbons.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound having a lactone structure with the chemical formula: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The compound of  claim 1 , which enhances PPARα, δ and γ agonist activities. 
     
     
         3 . A lifestyle disease improving drug containing a compound having a chemical formula selected from the group consisting of: 
       
         
           
           
               
               
           
         
         wherein the lifestyle disease improving drug enhances PPARα, δ and γ agonist activities. 
       
     
     
         4 . The lifestyle disease improving drug of  claim 3 , wherein the compound has the chemical formula: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The lifestyle disease improving drug of  claim 3 , wherein the compound has the chemical formula: 
       
         
           
           
               
               
           
         
       
     
     
         6 . The lifestyle disease improving drug of  claim 3 , wherein the compound has the chemical formula:

Join the waitlist — get patent alerts

Track US2016024041A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.